From 25.06.2020 to 25.06.2020

Starts at 18:00 until 19:30

Radiopharmaceuticals – in times of (Radio)Theranostics

Venue: Virtual
Speaker: Prof. Dr. Klaus Kopka
Organizer: HIRO, OncoRay and DKTK
Language: English
Registration necessary: yes


Radiation research and radiotherapy in oncology are highly interdisciplinary fields: physicians, scientists like biologists and physicists as well as engineers and computer experts are closely collaborating within the Heidelberg Institute of Radiation Oncology (HIRO) and OncoRay in Dresden.

The established cooperation of HIRO and OncoRay was awarded by BMBF as the National Center for Radiation Research in Oncology (NCRO).

To train young scientists in interdisciplinary research work is a special responsibility of HIRO, DKFZ and OncoRay. An important condition for a fruitful scientific collaboration is an active communication between researchers and consequently a common knowledge of the fundamentals of the whole field. This will be supported by this series of 18 lectures in 2 years.

The lectures cover a wide spectrum of topics from medicine, biology, chemistry, physics and technology being relevant for the research at HIRO Heidelberg and OncoRay Dresden. Each lecture will give a commonly understandable overview on a particular topic.

Therefore, all PhD students of the DKFZ, the Heidelberg university hospital and OncoRay as well as collaborating institutions and all other interested persons are cordially invited to join the lectures!


Radiopharmaceuticals are radiolabelled drugs usually administered in Nuclear Medicine clinics for diagnosis by means of non-invasive PET/CT, PET/MRI and SPECT/CT imaging or for systemic internal therapy, nowadays called targeted endoradiotherapy. The (historic) radiotracer/radioindicator principle at the moment experiences a renaissance by the clinically introduced  classes  of  theranostic  radiotracers,  which  enable  highly  sensitive  and  selective imaging  of  receptors/proteins  abnormally  upregulated  in  a  given  disease  (e.g.  cancer).  This imaging  approach  is  needed  to  justify  and  to  assess  the  probability  of  successful  targeted treatment  by  endoradiotherapy,  using  the  same  class  of  tracer  molecules.  This  lecture  will reflect the radiotracer principle using the class of theranostic radioligands. The complexity will be  addressed  how  to  combine  diagnosis  and  therapy  in  Nuclear  Medicine  with  one  and  the same class of tracer molecule.

For more information and access to the virtual meeting Room, please contact marcel.schaefer(at)

Program Lecture Series

We use cookies to make our website more user-friendly. Further information can be found in the data protection policy (privacy policy). To data protection policy